Business · 16/03/2023Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to Reata Pharmaceuticals for Rare Pediatric Disease Product
Summary
The FDA has awarded a priority review voucher to Reata Pharmaceuticals, Inc. for its rare pediatric disease product SKYCLARYS, following a review of the product's approval on February 28, 2023.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →